Trials / Unknown
UnknownNCT03262207
Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours
Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours: Potential Risks and Consequences for the Conceptus
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 90 (actual)
- Sponsor
- Centre Hospitalier Universitaire Dijon · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
Recent data suggest that sperm cells carry an epigenetic message during spermatogenesis and that this message is crucial for the future development of the embryo. This epigenetic signature is notably represented by methylation of genes subjected to imprinting (GSI) and the methylation of transposable elements (TE). Data on the maintenance of the imprint and of the control of TE accompanying human gametogenesis in a context of adult germinal testicular cancers, seminomas, are extremely fragmentary for tumour tissues and inexistent for gametes. The aim of this study is to determine whether patients with seminomas in comparison with fertile men carry a higher risk of presenting epigenetic alterations affecting their gametes. This study is based on the use of an existing collection of biological samples. 90 samples will be selected and split into 3 groups: * Group 1: 30 sperm samples from patients with seminomatous testicular tumours * Group 2: 30 sperm samples from fertile patients * Group 3: 30 sperm samples from infertile patients After treatment of the samples (thawing, cell sorting and removal of cryoprotectants), they will be analysed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Extraction genomic DNA | |
| OTHER | Analysis of methylation profiles of numerous GSI and TE | |
| OTHER | Analysis of methylation for the whole genome (sub-population of 15 samples from group 1) | |
| OTHER | Method of protein detection by immunostaining and flow cytometry |
Timeline
- Start date
- 2016-09-01
- Primary completion
- 2017-09-01
- Completion
- 2017-09-01
- First posted
- 2017-08-25
- Last updated
- 2017-08-25
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03262207. Inclusion in this directory is not an endorsement.